<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401879</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-210417</org_study_id>
    <nct_id>NCT03401879</nct_id>
  </id_info>
  <brief_title>Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis</brief_title>
  <official_title>Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global&#xD;
      median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects&#xD;
      twice as many women as men. MS is traditionally diagnosed by the presentation of lesions of&#xD;
      the central nervous system, disseminated in time and in space, proven by clinical examination&#xD;
      and magnetic resonance imaging. Several anatomical parameters in the eye, both vascular and&#xD;
      neural, have been found to be altered in MS patients.&#xD;
&#xD;
      Because of its unique optical properties, the eye offers the possibility of the non-invasive&#xD;
      assessment of both structural and functional alterations in neuronal tissue. As the&#xD;
      neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative&#xD;
      changes in the brain are accompanied by structural and possibly also functional changes in&#xD;
      the neuro-retina and the ocular vasculature.&#xD;
&#xD;
      The current study seeks to test the hypothesis that beside the known anatomical changes, also&#xD;
      functional changes can be detected in the retina of patients with MS. For this purpose,&#xD;
      flicker light induced hyperemia will be measured in the retina as a functional test to assess&#xD;
      the coupling between neural activity and blood flow. Further, structural parameters such as&#xD;
      retinal nerve fiber layer thickness and function parameters such as ocular blood flow and&#xD;
      retinal oxygenation will be assessed and compared to age and sex matched controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flicker induced increase in retinal blood flow</measure>
    <time_frame>1 day</time_frame>
    <description>Response of retinal blood flow to flicker light assessed with FDOCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel diameters</measure>
    <time_frame>1 day</time_frame>
    <description>Response of retinal vessel diameters to flicker light assessed with DVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal oxygen saturation</measure>
    <time_frame>1 day</time_frame>
    <description>Retinal oxygen saturation measured with DVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fiber layer thickness</measure>
    <time_frame>1 day</time_frame>
    <description>Retinal nerve fiber layer thickness measured using OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Layer specific flow signal</measure>
    <time_frame>1 day</time_frame>
    <description>Retinal layer specific blood flow signal measured using OCTA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Patients with MS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Multiple Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy age- and sex- matched control subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dynamic Vessel Analyzer (DVA)</intervention_name>
    <description>Retinal vessel diameters and oxygen saturation will be measured with the DVA device.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with MS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fourier Domain Doppler Optical Coherence Tomography (FDOCT)</intervention_name>
    <description>Retinal blood flow will be assessed using FDOCT.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with MS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical coherence tomography (OCT)</intervention_name>
    <description>Nerve fiber layer thickness and central retinal thickness will be measured using OCT.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with MS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical coherence tomography angiography (OCTA)</intervention_name>
    <description>Retinal microvasculature will be assessed using OCTA.</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with MS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for healthy subjects:&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Normal findings in the medical history unless the investigator considers an&#xD;
             abnormality to be clinically irrelevant&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropy &lt; 6 Dpt.&#xD;
&#xD;
        Inclusion criteria for patients with MS:&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
          -  Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to clinical&#xD;
             evaluation and McDonald criteria (revision 2010)&#xD;
&#xD;
          -  History of AON in one eye at least one year ago&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropy &lt; 6 Dpt.&#xD;
&#xD;
          -  Adequate visual acuity to allow participation in the ocular blood flow measurements&#xD;
&#xD;
          -  A potential participant has to be on stable doses of all medications he/she is taking&#xD;
             because of consisting illnesses according to medical history (except MS therapy itself&#xD;
             which will be recorded separately) for at least 30 days prior inclusion, if considered&#xD;
             relevant by the investigator.&#xD;
&#xD;
        Any of the following will exclude a healthy subject from the study:&#xD;
&#xD;
          -  Diagnosis of &quot;possible MS&quot; according to the McDonald criteria (revision 2010)&#xD;
&#xD;
          -  Presence or history of a severe medical condition as judged by the clinical&#xD;
             investigator&#xD;
&#xD;
          -  Untreated Arterial hypertension&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements in the study eye as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  Family history of MS, optic neuritis, neuromyelitis optica (NMO, Devic disease) or NMO&#xD;
             spectrum disorders&#xD;
&#xD;
          -  History of inflammatory or infectious disease of central nervous system&#xD;
&#xD;
          -  Best corrected visual acuity &lt; 0.5 Snellen&#xD;
&#xD;
          -  Ametropy â‰¥ 6Dpt&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
&#xD;
          -  Alcoholism or substance abuse&#xD;
&#xD;
        Any of the following will exclude a patient from the study:&#xD;
&#xD;
          -  Presence or history of a severe medical condition other than MS as judged by the&#xD;
             clinical investigator&#xD;
&#xD;
          -  History of neuromyelitis optica (NMO, Devic disease) or NMO spectrum disorders&#xD;
&#xD;
          -  History of inflammatory or infectious disease of central nervous system other than MS&#xD;
&#xD;
          -  Untreated Arterial hypertension&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements in the study eye as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  Best corrected visual acuity &lt; 0.5 Snellen&#xD;
&#xD;
          -  Ametropy â‰¥ 6 Dpt&#xD;
&#xD;
          -  Pregnancy, planned pregnancy&#xD;
&#xD;
          -  Significant neurological disease other than MS, if considered relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Alcoholism or substance abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard GarhÃ¶fer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard GarhÃ¶fer, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@medunwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard GarhÃ¶fer, MD</last_name>
      <phone>0043140400</phone>
      <phone_ext>29810</phone_ext>
    </contact>
    <investigator>
      <last_name>Gerhard GarhÃ¶fer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Section Head Ophthalmo-Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

